3P association (3PAs): Pituitary adenoma and pheochromocytoma/paraganglioma. A heterogeneous clinical syndrome associated with different gene mutations
Fernando Guerrero‐Pérez(Bellvitge University Hospital), Carles Villabona(Bellvitge University Hospital), Olga Giménez‐Palop(Corporació Sanitària Parc Taulí), Mercedes Robledo(The University of Texas at San Antonio Health Science Center), Tomás Martín Hernández(Centro de Ingeniería Genética y Biotecnología), Natividad González(Hospital Universitario Virgen Macarena), Juan J. Díez(Instituto Cajal), Carmen Fajardo(Hospital Universitari Germans Trias i Pujol), Arturo Lisbona Gil(Hospital Central de la Defensa Gómez Ulla), Elena Torres Vela(Instituto de Investigación Biosanitaria de Granada), Pedro Iglesias(Hospital Universitario Puerta de Hierro Majadahonda)
Cited by 20
Related Papers
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma
|Nature Genetics|2011|528
Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension
|Journal of Hypertension|2020|406
Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas
|Human Molecular Genetics|2013|394
An Update on the Genetics of Paraganglioma, Pheochromocytoma, and Associated Hereditary Syndromes
|Hormone and Metabolic Research|2012|287
SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma
|The Lancet Oncology|2010|274